The World Health Organization announced on the 17th to stop its “solidarity trial” project hydroxychloroquine branch trial, on the grounds that the drug failed to reduce the mortality rate of newly crowned patients. WHO’s Department of Immunization, Vaccines and Biologicals Official Restrepo said at a regular press conference the same day, based on the analysis and review of the published evidence, the trial implementation team after careful consideration, decided to stop the “solidarity trial” project hydroxychloroquine branch trial.
Internal and other external evidence from the Solidarity Trials shows that hydroxychloroquine does not reduce the patient’s mortality rate compared to standard treatments for patients with new crowns, Restrepo said.
She stressed that the cessation of the hydroxychloroquine branch trial did not constitute a WHO policy, nor was it a WHO policy recommendation. “This is what we are doing for the ‘solidarity trial’ for new crown patients … WHO has different procedures for developing guidelines. “
WHO said in a statement the same day, “solidarity trial” researchers will no longer randomly assign patients to hydroxychloroquine branch, has begun to take hydroxychloroquine but has not completed the course of treatment in the trial, can complete the course under the guidance of a supervised physician or stop taking.
THE WHO SOLIDARITY TRIAL AIMS TO COMPARE THE SAFETY AND EFFECTIVENESS OF SEVERAL DIFFERENT DRUGS OR COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEW CORONARY PNEUMONIA IN ORDER TO FIND EFFECTIVE TREATMENTS AS QUICKLY AS POSSIBLE. (Complete)
Originally: WHO announces halt to new crown trial for hydroxychloroquine treatment